Tango Therapeutics, Inc. (TNGX) research
Tango Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $24.63
- As of
Tango Therapeutics, Inc. (TNGX): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-11.
As of . Source: SEC EDGAR filings for TNGX. Method and limitations.
Share the TNGX intelligence card
See TNGX live in the terminal
Track TNGX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live TNGX terminal, freeActive signals for TNGX
- highCONSENSUS_BUY
3 tracked funds increased TNGX this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +1253% to TNGX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +725% to TNGX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1461% to TNGX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +439% to TNGX (2026Q2)
FREE, NO ACCOUNT
Every signal on TNGX, as it fires
You are seeing 5 of 18 signals recorded on TNGX since 2026-05-26.
The five above landed across 2 days. The other 13 were recorded on 4 other days. 14 of the 18 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TNGX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 87583X109 · 2026Q2 | $23.4M | 0.03% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 87583X109 · 2026Q2 | $15.5M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP 87583X109 · 2026Q2 | $9.3M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 87583X109 · 2026Q2 | $7.6M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 87583X109 · 2026Q2 | $5.7M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TNGX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TNGX against its peers
TNGX's operating margin of -178.4% ranks in the 39th percentile of 13 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | TNGX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 62.4M USD | 219M USD | 41 | 15 |
| Operating margin | -178.4% | -72.8% | 39 | 13 |
| Net margin | -162.9% | -52.0% | 39 | 13 |
| Return on equity | -29.3% | -32.5% | 59 | 22 |
Peers (23): CELC, ELVN, RLAY, CPRX, TLX, MANE, IDYA, IOVA, GRAL, ACAD, EWTX, LEGN, GRTX, VKTX, DYN, DFTX, DNLI, VCYT, RCUS, ERAS, APLS, DNTH, CLDX. Left out: PBLS (no annual filing), ZLDPF (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (TNGX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more TNGX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TNGXand get the insider, 13F, options, and confluence read in one view.